{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:36:22Z","timestamp":1764732982781,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In this prospective observational cohort study we analyzed cellular and serological immune response parameters against SARS-CoV-2 and current variants of concern (VOC) in 147 COVID-19-convalescent and 39 COVID-19-na\u00efve individuals before and after BNT162b2 booster vaccination. No significant differences regarding immunological response parameters were observed between younger and older individuals. Booster vaccination induced full recovery of both cellular and serological response parameters including IFN-\u03b3 secretion and anti-spike antibody titers with strong neutralization capacities against wild type SARS-COV-2 and Delta. Surprisingly, even serological neutralization capacity against Omicron was detectable one month after second vaccination and four months before it had been first observed in South Africa. As a result, more than 90% of convalescent individuals exhibited detectable and 75% strong Omicron neutralization capacity after booster vaccination, compared with 72% and 46% of COVID-19-na\u00efve individuals. Our results support the notion that broad and cross-reactive immune memory against SARS-CoV-2 including currently known VOCs can be established by booster vaccination with spike-based mRNA vaccines like BNT162b2, particularly in COVID-19-convalescent individuals of all ages. Nevertheless, especially in COVID-19-na\u00efve individuals future variants escaping the memory immune response may require vaccine approaches such as <jats:italic>inactivated whole virus vaccines<\/jats:italic>, which include all antigenic components of the virus.<\/jats:p>","DOI":"10.3389\/fimmu.2022.920210","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T04:31:03Z","timestamp":1655699463000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages"],"prefix":"10.3389","volume":"13","author":[{"given":"Bernd","family":"Jahrsd\u00f6rfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Proffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janina","family":"H\u00e4gele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Vieweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Grempels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorit","family":"Fabricius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramin","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixten","family":"K\u00f6rper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.chom.2022.01.005","article-title":"SARS-CoV-2 Prolonged Infection During Advanced HIV Disease Evolves Extensive Immune Escape","volume":"30","author":"Cele","year":"2022","journal-title":"Cell Host Microbe"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03944.x","article-title":"Vaccines for the Elderly","author":"Weinberger","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.021","article-title":"Risk Factors of Critical & Mortal COVID-19 Cases: A Systematic Literature Review and Meta-Analysis","volume":"81","author":"Zheng","year":"2020","journal-title":"J Infect"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"8870249","DOI":"10.1155\/2020\/8870249","article-title":"The Impact of COVID-19 Pandemic on Long-Term Care Facilities Worldwide: An Overview on International Issues","volume":"2020","author":"Thompson","year":"2020","journal-title":"BioMed Res Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.743422","article-title":"BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents","volume":"12","author":"Jahrsd\u00f6rfer","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19885","article-title":"Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged >\/=60 Years","volume":"326","author":"Eliakim-Raz","year":"2021","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4390","article-title":"Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment","volume":"7","author":"Eliakim-Raz","year":"2021","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2021.2012.2019.21268037","DOI":"10.1038\/s41590-022-01212-3","article-title":"Superior Immunogenicity and Effectiveness of the 3rd BNT162b2 Vaccine Dose","author":"Lustig","year":"2022","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2021.05.017","article-title":"Emerging Evidence on Effectiveness of COVID-19 Vaccines Among Residents of Long-Term Care Facilities","volume":"22","author":"Salcher-Konrad","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab584","article-title":"Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience","volume":"225","author":"Gilboa","year":"2022","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron Extensively But Incompletely Escapes Pfizer BNT162b2 Neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3390\/vaccines9080918","article-title":"mRNA Vaccines Enhance Neutralizing Immunity Against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects","volume":"9","author":"Fabricius","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj9853","article-title":"Low-Dose mRNA-1273 COVID-19 Vaccine Generates Durable Memory Enhanced by Cross-Reactive T Cells","volume":"374","author":"Mateus","year":"2021","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04460-3","article-title":"T Cell Responses to SARS-CoV-2 Spike Cross-Recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 Vaccination Induces Immunological T Cell Memory Able to Cross-Recognize Variants From Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA Vaccines Induce Persistent Human Germinal Centre Responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing Antibody Levels are Highly Predictive of Immune Protection From Symptomatic SARS-CoV-2 Infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115624","article-title":"BNT162b2 Vaccine Booster and Mortality Due to Covid-19","volume":"385","author":"Arbel","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 Vaccine Booster Against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/infdis\/jiaa656","article-title":"Independent Side-By-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing","volume":"223","author":"Jahrsd\u00f6rfer","year":"2021","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100036","article-title":"Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors","volume":"206","author":"Jahrsd\u00f6rfer","year":"2021","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"n1605","DOI":"10.1136\/bmj.n1605","article-title":"How Long Does Covid-19 Immunity Last","volume":"373","author":"Baraniuk","year":"2021","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in Boosting COVID-19 Vaccine Immune Responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"103904","DOI":"10.1016\/j.ebiom.2022.103904","article-title":"Waning Immune Responses Against SARS-CoV-2 Variants of Concern Among Vaccinees in Hong Kong","volume":"77","author":"Peng","year":"2022","journal-title":"EBioMedicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103761","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous ChAdOx1 Ncov-19 and BNT162b2 Prime-Boost Vaccination Elicits Potent Neutralizing Antibody Responses and T Cell Reactivity Against Prevalent SARS-CoV-2 Variants","volume":"75","author":"Gross","year":"2022","journal-title":"EBioMedicine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid Epidemic Expansion of the SARS-CoV-2 Omicron Variant in Southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj1031","article-title":"Impaired Humoral Immunity to SARS-CoV-2 BNT162b2 Vaccine in Kidney Transplant Recipients and Dialysis Patients","volume":"6","author":"Rincon-Arevalo","year":"2021","journal-title":"Sci Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150175","article-title":"Impaired Humoral and Cellular Immunity After SARS-CoV-2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients","volume":"131","author":"Sattler","year":"2021","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690698","article-title":"Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis","volume":"12","author":"Schrezenmeier","year":"2021","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.12.21261966","article-title":"B and T Cell Responses After a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients","volume":"32","author":"Schrezenmeier","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/art.42060","article-title":"B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab","volume":"74","author":"Stefanski","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157836","article-title":"Temporary Antimetabolite Treatment Hold Boosts SARS-CoV-2 Vaccination-Specific Humoral and Cellular Immunity in Kidney Transplant Recipients","volume":"7","author":"Schrezenmeier","year":"2022","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","first-page":"21601","DOI":"10.1038\/s41598-021-00844-z","article-title":"Cross-Reactivity of Antibodies From non-Hospitalized COVID-19 Positive Individuals Against the Native, B.1.351, B.1.617.2 and P.1 SARS-CoV-2 Spike Proteins","volume":"11","author":"Hojjat Jodaylami","year":"2021","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","article-title":"Immunological Memory to SARS-CoV-2 Assessed for Up to 8 Months After Infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.920210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T04:31:05Z","timestamp":1655699465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.920210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2022.920210"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.920210","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"article-number":"920210"}}